# OnCo record serd (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/serd/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "serd" ;
  schema:name "Selective oestrogen receptor degrader (SERD)"@en ;
  schema:alternateName "SERD"@en, "SERDs"@en, "oral SERDs"@en, "ER degrader"@en, "estrogen receptor degrader"@en, "SERM"@en, "selective oestrogen receptor modulator"@en, "CERAN"@en, "PROTAC ER degrader"@en, "oestrogen receptor degrader"@en ;
  schema:description "Drugs that do not just block the oestrogen receptor but mark it for destruction, so the cancer cell loses the receptor altogether. The new oral versions work even when the receptor has mutated (ESR1) to escape older hormone pills."@en ;
  schema:url <https://onco.cc/terms/serd/> ;
  schema:dateModified "2026-09-09"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Selective_estrogen_receptor_degrader> ;
  schema:citation <https://en.wikipedia.org/wiki/Selective_estrogen_receptor_degrader> ;
  onco:related <https://onco.cc/terms/endocrine-resistance/>, <https://onco.cc/terms/aromatase-inhibitor/>, <https://onco.cc/terms/hormone-receptor-status/> ;
  onco:cancers <https://onco.cc/cancers/breast-hr-positive/> ;
  onco:sections <https://onco.cc/fronts/hormonal/> ;
  onco:technologies <https://onco.cc/technologies/endocrine-therapy/>, <https://onco.cc/technologies/protac-degrader/> ;
  onco:targets <https://onco.cc/targets/estrogen-receptor/> ;
  onco:drugs <https://onco.cc/drugs/fulvestrant/>, <https://onco.cc/drugs/elacestrant/>, <https://onco.cc/drugs/tamoxifen/> ;
  onco:trials <https://onco.cc/trials/emerald/>, <https://onco.cc/trials/serena-6/> .